A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months through 5 years old and Pfizer’s three-dose COVID-19 vaccine for children aged 6 months through 4 years old. Based on the scientific evidence available, the committee agreed that each vaccine’s benefits outweigh its risks in these age groups. Yesterday, the committee also voted to recommend FDA authorize Moderna’s vaccine for children age 6-17, which would provide an alternative to the currently authorized Pfizer vaccine for this age group.

Before vaccinations can begin, FDA must authorize and the Centers for Disease Control and Prevention recommend the vaccines for these age groups. CDC’s Advisory Committee on Immunization Practices could consider the issue as soon as June 17-18.
 

Related News Articles

#HealthCareInnovation Blog
In the fall of 2021, two years into the COVID-19 pandemic in the U.S., nearly 80% of adults said they had heard “at least one of eight different false…
Headline
Summertime is right around the corner and AHA’s new social media toolkit promotes COVID-19 vaccination and boosters as a means for keeping kids active and…
Headline
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain…
Headline
In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76%…
Headline
The Centers for Disease Control and Prevention April 19 recommended a second Moderna or Pfizer COVID-19 bivalent vaccine dose for adults aged 65 and older…
Headline
The Department of Health and Human Services on April 19 announced a $1.1 billion public-private partnership to help maintain access to COVID-19…